Methods for controlling pain in canines using a transdermal solution of fentanyl
View Patent ↗This invention provides methods of controlling pain in a canine comprising transdermally administering a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution. The invention also provides a single unit dose of the composition.
1. A method of controlling pain for an effective period of time comprising transdermally administering to a canine in need thereof a therapeutically effective amount of a composition comprising fentanyl, a penetration enhancer, and a volatile liquid, wherein the composition is a solution, and the transdermal administration is applied to a dorsal location of the canine.
2. The method of claim 1 wherein the composition is administered as a single dose.
3. The method of claim 1 wherein the effective period of time is at least about 96 hours.
4. A method of treating pain comprising transdermally administering to a canine in need of treatment a therapeutically effective amount of a composition comprising fentanyl, a penetration enhancer, and a volatile liquid,
wherein the composition is a solution and is administered as a single dose, and
wherein the single dose is effective for the treatment of pain for at least about 96 hours, and the transdermal administration is applied to a dorsal location of the canine.
5. The method of claim 4 wherein the transdermal administration is applied to the dorsal interscapular location of the canine.
6. The method of claim 1 wherein the penetration enhancer is octyl salicylate.
7. The method of claim 1 wherein the volatile liquid is isopropanol.
8. The method of claim 1 wherein the pain is associated with a surgery performed or to be performed on the canine.
9. The method of claim 8 wherein the surgery is an orthopedic surgery.
10. The method of claim 8 wherein the surgery is a soft tissue surgery.
11. The method of claim 8 wherein the composition is administered to the canine about 2 to about 4 hours prior to the surgery.
12. The method of claim 11 wherein the composition is administered as a single dose.
13. The method of claim 1 wherein the composition is administered as a single unit dose.
14. The method of claim 1 wherein the composition comprises about 0.1 to about 10% (w/v) of fentanyl, about 0.1 to about 10% (w/v) of the penetration enhancer, and about 80 to about 99.8% (w/v) of the volatile liquid.
15. The method of claim 1 wherein the composition comprises about 3 to about 7% (w/v) of fentanyl, about 3 to about 7% (w/v) of the penetration enhancer, and about 86 to about 94% (w/v) of the volatile liquid.
16. The method of claim 1 wherein the composition comprises about 5% (w/v) of fentanyl, about 5% (w/v) of the penetration enhancer, and about 90% (w/v) of the volatile liquid.
17. The method of claim 16 wherein the penetration enhancer is octyl salicylate and the volatile liquid is isopropanol.
18. The method of claim 1 wherein the fentanyl is administered at a dose of about 0.1 to about 10 mg/kg of weight of the canine.
19. The method of claim 1 wherein the fentanyl is administered at a dose of about 1 to about 5 mg/kg of weight of the canine.
20. The method of claim 1 wherein the fentanyl is administered at a dose of about 2.7 mg/kg of weight of the canine.
21. The method of claim 1 wherein the composition is administered with one or more other therapeutic ingredients.
22. The method of claim 1 wherein the composition is administered using a transdermal dispensing apparatus.
23. The method of claim 1 wherein said dorsal location is the dorsal interscapular location.
24. The method of claim 4 wherein the pain is associated with a surgery performed or to be performed on the canine.
25. The method of claim 24 wherein the surgery is an orthopedic surgery.
26. The method of claim 24 wherein the surgery is a soft tissue surgery.
27. The method of claim 24 wherein the composition is administered to the canine about 2 to about 4 hours prior to the surgery.
28. The method of claim 4 wherein the composition comprises about 0.1 to about 10% (w/v) of fentanyl, about 0.1 to about 10% (w/v) of the penetration enhancer, and about 80 to about 99.8% (w/v) of the volatile liquid.
29. The method of claim 4 wherein the composition comprises about 3 to about 7% (w/v) of fentanyl, about 3 to about 7% (w/v) of the penetration enhancer, and about 86 to about 94% (w/v) of the volatile liquid.
30. The method of claim 4 wherein the composition comprises about 5% (w/v) of fentanyl, about 5% (w/v) of the penetration enhancer, and about 90% (w/v) of the volatile liquid.
31. The method of claim 30 wherein the penetration enhancer is octyl salicylate and the volatile liquid is isopropanol.
32. The method of claim 4 wherein the fentanyl is administered at a dose of about 0.1 to about 10 mg/kg of weight of the canine.
33. The method of claim 4 wherein the fentanyl is administered at a dose of about 1 to about 5 mg/kg of weight of the canine.
34. The method of claim 4 wherein the fentanyl is administered at a dose of about 2.7 mg/kg of weight of the canine.
35. The method of claim 4 wherein the composition is administered with one or more other therapeutic ingredients.
36. The method of claim 4 wherein the composition is administered using a transdermal dispensing apparatus.